Elscint names Sardano to NM post
Israeli multimodality vendor Elscint has named Joe Sardano head of its U.S. nuclear medicine business unit, a position that previously had been vacant. Prior to joining Elscint in November, Sardano was with Fisher Scientific, and has also worked for
Israeli multimodality vendor Elscint has named Joe Sardano head of its U.S. nuclear medicine business unit, a position that previously had been vacant. Prior to joining Elscint in November, Sardano was with Fisher Scientific, and has also worked for Park, Toshiba, and Diasonics. Sardano said his priorities in the position are to expand Elscint's sales force, broaden the company's marketing efforts, and improve the vendor's customer satisfaction levels in the U.S.
Sardano will report to Eliezer Tokman, the Elscint CT veteran who was named to head the company's Americas regional operations in a restructuring announced in November (SCAN 11/12/97). Elscint is moving its global nuclear medicine headquarters to the U.S. as part of the restructuring.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
